A detailed history of Baker Bros. Advisors LP transactions in Xencor Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 545,431 shares of XNCR stock, worth $10.3 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
545,431
Previous 245,431 122.23%
Holding current value
$10.3 Million
Previous $5.21 Million 131.67%
% of portfolio
0.15%
Previous 0.06%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $5.6 Million - $7.96 Million
300,000 Added 122.23%
545,431 $12.1 Million
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $2.02 Million - $2.62 Million
122,304 Added 99.33%
245,431 $5.21 Million
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $3.05 Million - $3.8 Million
123,127 New
123,127 $3.21 Million
Q2 2021

Aug 16, 2021

SELL
$34.33 - $44.68 $12.7 Million - $16.5 Million
-369,370 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$36.63 - $47.63 $1.49 Million - $1.94 Million
-40,772 Reduced 9.94%
369,370 $16.1 Million
Q3 2020

Nov 16, 2020

SELL
$30.09 - $43.02 $540,958 - $773,413
-17,978 Reduced 4.2%
410,142 $15.9 Million
Q1 2019

May 15, 2019

SELL
$27.85 - $38.09 $336,038 - $459,593
-12,066 Reduced 2.74%
428,120 $13.3 Million
Q4 2018

Feb 13, 2019

SELL
$32.39 - $42.05 $5.26 Million - $6.83 Million
-162,309 Reduced 26.94%
440,186 $15.9 Million
Q3 2018

Nov 14, 2018

SELL
$35.69 - $47.65 $9.62 Million - $12.8 Million
-269,577 Reduced 30.91%
602,495 $23.5 Million
Q3 2017

Nov 14, 2017

BUY
$19.61 - $23.35 $17.1 Million - $20.4 Million
872,072
872,072 $20 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.13B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.